Apnimed

39 John F Kennedy Street Cambridge MA 02138 US

JOBS

IN THE PRESS

Drug Development

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

December 16, 2021

·

5 min read

Drug Development

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

October 13, 2021

·

6 min read

Drug Development

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

October 13, 2021

·

7 min read

Business

Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer

September 27, 2021

·

3 min read

Genetown

Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference

August 6, 2021

·

2 min read

Business

David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed

July 27, 2021

·

4 min read

Genetown

Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference

July 6, 2021

·

2 min read